PT - JOURNAL ARTICLE AU - HYE YOUNG CHOI AU - HYO JUNG LEE AU - KYOUNG MI MOON AU - DONG KYU MOON AU - SECHAN LEE AU - HYEWON PARK AU - JINPYO HONG AU - MI JUNG PARK AU - DONG KYUN WOO AU - JAE CHEAL YOO TI - Up-regulation of CPNE1 Appears to Enhance Cancer Progression in HER2-positive and Luminal A Breast Cancer Cells AID - 10.21873/anticanres.15831 DP - 2022 Jul 01 TA - Anticancer Research PG - 3445--3452 VI - 42 IP - 7 4099 - http://ar.iiarjournals.org/content/42/7/3445.short 4100 - http://ar.iiarjournals.org/content/42/7/3445.full SO - Anticancer Res2022 Jul 01; 42 AB - Background/Aim: Copine 1 (CPNE1) is a calciumdependent phospholipid protein that has been shown to regulate the AKT serine/threonine kinase 1 (AKT) signaling pathway to mediate its function in various cell types. However, little is known about the physiological function of this protein in breast cancer cells. We aimed to investigate the prognostic and therapeutic value of CPNE1 in erb-b2 receptor tyrosine kinase 2 [human epidermal growth factor receptor 2 (HER2)]-positive and luminal A subtypes of breast cancer. Materials and Methods: Western blotting, cell viability, wound-healing and invasion assays were performed on SK-BR3 and MCF-7 breast cancer cells with forced overexpression of CPNE1. CPNE1 immunohistochemical (IHC) staining and bioinformatics analysis were performed on specimens from patients with breast cancer and compared to normal breast samples. Results: CPNE1 overexpression promoted AKT activation, and increased cell viability and cell motility in SK-BR3 and MCF-7 breast cancer cells. In addition, invasive capabilities of SK-BR3 cells were increased by the overexpression of CPNE1. The expression levels of CPNE1 were higher in HER2-positive and luminal A subtypes of human breast cancer tissues compared with those in adjacent normal tissues. Furthermore, CPNE1 expression was increased in RNA microarray analysis of samples from patients with breast cancer compared to normal breast samples. Conclusion: CPNE1 may play a key role in the pathophysiology of HER2-positive and luminal A subtypes of breast cancer.